Foamcraft Inc., an Indianapolis-based foam-products manufacturer than began selling mattresses less than two years ago, plans to compete directly with online mattress behemoths such as Casper, Leesa and Purple.
Boiling down the dozen pitches from budding entrepreneurs at Thursday's Startup Bowl reveals vital themes: the mammoth influence of mobile, an intense craving for consumer data, and the relentless pursuit of revenue.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.